Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma

Journal of Dermatological Science

Volumn 62, Issue 2, 2011, Pages 75-83

  Schlapbach, Christoph ^a   Yerly, Daniel ^a   Daubner, Barbara ^a   Yawalkar, Nikhil ^a   Hunger, Robert E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

CCR4; CCR6; Cutaneous T cell lymphoma (CTCL); Granulocyte monocyte colony stimulating factor (GM CSF); GV1001; HTERT specific peptide vaccination; Regulatory T cells (Treg); Skin homing receptors; Telomerase; Tumor vaccination

Indexed keywords

CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TERTOMOTIDE;

ADULT; AGED; ARTICLE; CANCER GROWTH; CELL EXPANSION; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; IN VITRO STUDY; INJECTION SITE IRRITATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; LYMPHOCYTE DEPLETION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIDE EFFECT; SKIN REDNESS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; VACCINE FAILURE;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; DISEASE PROGRESSION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNE SYSTEM; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES; TELOMERASE; TREATMENT OUTCOME; VACCINES, SUBUNIT;

EID: 79954602211     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2011.02.001     Document Type: Article

References (42)

1. Willemze R., Jaffe E.S., Burg G., Cerroni L., Berti E., Swerdlow S.H., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105(10):3768-3785.
2. Scarisbrick J.J., Whittaker S., Evans A.V., Fraser-Andrews E.A., Child F.J., Dean A., et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 2001, 97(3):624-630.
3. Dummer R., Cozzio A., Meier S., Beyeler M., Laetsch B., Doebbeling U., et al. Standard and experimental therapy in cutaneous T-cell lymphomas. J Cutan Pathol 2006, 33(Suppl. 1):52-57.
4. Harley C.B. Telomerase and cancer therapeutics. Nat Rev Cancer 2008, 8(3):167-179.
5. Tian X., Chen B., Liu X. Telomere and telomerase as targets for cancer therapy. Appl Biochem Biotechnol 2010, 160(5):1460-1472.
6. Kyte J.A. Cancer vaccination with telomerase peptide GV1001. Expert Opin Investig Drugs 2009, 18(5):687-694.
7. Brunsvig P.F., Aamdal S., Gjertsen M.K., Kvalheim G., Markowski-Grimsrud C.J., Sve I., et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 2006, 55(12):1553-1564.
8. Kokhaei P., Palma M., Hansson L., Osterborg A., Mellstedt H., Choudhury A. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007, 35(2):297-304.
9. Shaw V.E., Naisbitt D.J., Costello E., Greenhalf W., Park B.K., Neoptolemos J.P., et al. Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Rev Vaccines 2010, 9(9):1007-1016.
10. Bernhardt S.L., Gjertsen M.K., Trachsel S., Moller M., Eriksen J.A., Meo M., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95(11):1474-1482.
11. Wu K., Lund M., Bang K., Thestrup-Pedersen K. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma. Cancer 1999, 86(6):1056-1063.
12. Wu K.D., Hansen E.R. Shortened telomere length is demonstrated in T-cell subsets together with a pronounced increased telomerase activity in CD4 positive T cells from blood of patients with mycosis fungoides and parapsoriasis. Exp Dermatol 2001, 10(5):329-336.
13. Xu D., Erickson S., Szeps M., Gruber A., Sangfelt O., Einhorn S., et al. Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells. Blood 2000, 96(13):4313-4318.
14. Zuolin Y., Jianfang S., Shan L. Detection of telomerase activity in patients with mycosis fungoides. Chin Med Sci J 2003, 18(2):124-127.
15. Schlapbach C., Ochsenbein A., Kaelin U., Hassan A.S., Hunger R.E., Yawalkar N. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol 2010, 62(6):995-1004.
16. Woetmann A., Lovato P., Eriksen K.W., Krejsgaard T., Labuda T., Zhang Q., et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007, 109(8):3325-3332.
17. Speiser D.E., Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010, 22(3):144-154.
18. Leen A.M., Rooney C.M., Foster A.E. Improving T cell therapy for cancer. Annu Rev Immunol 2007, 25:243-265.
19. Bonertz A., Weitz J., Pietsch D.H., Rahbari N.N., Schlude C., Ge Y., et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 2009, 119(11):3311-3321.
20. Klages K., Mayer C.T., Lahl K., Loddenkemper C., Teng M.W., Ngiow S.F., et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010, 70(20):7788-7799.
21. Surls J., Nazarov-Stoica C., Kehl M., Casares S., Brumeanu T.D. Differential effect of CD4+Foxp3+ T-regulatory cells on the B and T helper cell responses to influenza virus vaccination. Vaccine 2010, 28(45):7319-7330.
22. Yerly D., Heckerman D., Allen T., Suscovich T.J., Jojic N., Kadie C., et al. Design, expression, and processing of epitomized hepatitis C virus-encoded CTL epitopes. J Immunol 2008, 181(9):6361-6370.
23. Steinhoff M., Schopp S., Assaf C., Muche M., Beyer M., Sterry W., et al. Prevalence of genetically defined tumor cells in CD7 as well as CD26 positive and negative circulating T-cell subsets in Sezary syndrome. Leuk Res 2009, 33(1):88-99.
24. Atayar C., Poppema S., Visser L., van den Berg A. Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol 2006, 208(3):423-430.
25. Shen R., Ye Y., Chen L., Yan Q., Barsky S.H., Gao J.X. Precancerous stem cells can serve as tumor vasculogenic progenitors. PLoS One 2008, 3(2):pe1652.
26. Rigo A., Gottardi M., Zamo A., Mauri P., Bonifacio M., Krampera M., et al. Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. Mol Cancer 2010, 9:p273.
27. Bagot M., Echchakir H., Mami-Chouaib F., Delfau-Larue M.H., Charue D., Bernheim A., et al. Isolation of tumor-specific cytotoxic CD4+ and CD4+CD8dim+ T-cell clones infiltrating a cutaneous T-cell lymphoma. Blood 1998, 91(11):4331-4341.
28. Echchakir H., Bagot M., Dorothee G., Martinvalet D., Le Gouvello S., Boumsell L., et al. Cutaneous T cell lymphoma reactive CD4+ cytotoxic T lymphocyte clones display a Th1 cytokine profile and use a fas-independent pathway for specific tumor cell lysis. J Invest Dermatol 2000, 115(1):74-80.
29. Muranski P., Restifo N.P. Adoptive immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol 2009, 21(2):200-208.
30. Campbell J.J., Clark R.A., Watanabe R., Kupper T.S. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood 2010, 116(5):767-771.
31. Campbell D.J., Butcher E.C. Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 2002, 195(1):135-141.
32. Alvarez D., Harder G., Fattouh R., Sun J., Goncharova S., Stampfli M.R., et al. Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses. J Immunol 2005, 174(3):1664-1674.
33. Ali O.A., Emerich D., Dranoff G., Mooney D.J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med 2009, 1(8):8ra19.
34. Miyara M., Wing K., Sakaguchi S. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. J Allergy Clin Immunol 2009, 123(4):749-755. quiz 756-57.
35. Greten T.F., Forner A., Korangy F., N'Kontchou G., Barget N., Ayuso C., et al. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer 2010, 10:209.
36. Pacholczyk R., Kern J. The T-cell receptor repertoire of regulatory T cells. Immunology 2008, 125(4):450-458.
37. Waller E.K. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist 2007, 12(Suppl. 2):22-26.
38. Miyagaki T., Sugaya M., Fujita H., Ohmatsu H., Kakinuma T., Kadono T., et al. Eotaxins and CCR3 interaction regulates the Th2 environment of cutaneous T-cell lymphoma. J Invest Dermatol 2010, 130(9):2304-2311.
39. Berger C.L., Tigelaar R., Cohen J., Mariwalla K., Trinh J., Wang N., et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005, 105(4):1640-1647.
40. Yawalkar N., Ferenczi K., Jones D.A., Yamanaka K., Suh K.Y., Sadat S., et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003, 102(12):4059-4066.
41. Samimi S., Benoit B., Evans K., Wherry E.J., Showe L., Wysocka M., et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 2010, 146(12):1382-1388.
42. Ha S.J., West E.E., Araki K., Smith K.A., Ahmed R. Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 2008, 223:317-333.